John Paul DeJoria holds 9.4% of Telomir (TELO) common stock

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. shareholder John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust and in his individual capacity, reports beneficial ownership of 3,245,000 shares of common stock, representing 9.438% of the class. He has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Telomir, indicating a passive investment intent under the Schedule 13G framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 09:24 PM Learn about SEC filing dates

FAQ

What ownership stake does John Paul DeJoria report in Telomir (TELO)?

John Paul DeJoria reports beneficial ownership of 3,245,000 Telomir shares, representing 9.438% of the company’s common stock. This sizeable stake gives him notable exposure to Telomir while remaining below typical 10% thresholds that can trigger additional regulatory obligations.

Does John Paul DeJoria have sole voting power over his Telomir (TELO) shares?

Yes, he has sole voting power over 3,245,000 shares and reports no shared voting power. He also has sole dispositive power over the same number of shares, meaning he alone can decide how these shares are voted and whether they are sold.

Is John Paul DeJoria’s Telomir (TELO) stake intended to influence control of the company?

The filing states the securities were not acquired or held to change or influence control of Telomir. This language aligns with a passive investment approach under Schedule 13G rather than an activist or control-seeking position.

What percentage of Telomir (TELO) does 3,245,000 shares represent?

The filing reports that 3,245,000 Telomir common shares represent 9.438% of the class. This indicates a significant but minority holding, giving economic and voting influence without crossing typical 10% insider thresholds.

In what capacity is John Paul DeJoria reporting his Telomir (TELO) holdings?

He reports in a dual capacity as trustee of the John Paul DeJoria Family Trust and in his individual capacity. Together, these positions account for the disclosed 3,245,000 Telomir common shares beneficially owned.

What type of securities does John Paul DeJoria hold in Telomir (TELO)?

The filing identifies the securities as Telomir Pharmaceuticals, Inc. common stock, no par value, with CUSIP 87975F104. All ownership, voting power, and dispositive power figures in the filing relate to this class of common shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Telomir Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

87975F104

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87975F104

1

Names of Reporting Persons

John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,245,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,245,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,245,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.438 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Telomir Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 100 SE 2nd Street, Suite 2000 #1009, Miami, FL 33131
Item 2.
(a)	Name of person filing: John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
(b)	Address or principal business office or, if none, residence: The business address of Mr. DeJoria is 109 West 7th Street, Suite 200, Georgetown, Texas 78626
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock, no par value
(e)	CUSIP No.: 87975F104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,245,000
(b)	Percent of class: 9.438%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,245,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,245,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity

Signature:	/s/ Matthew R. Bair
Name/Title:	Matthew R. Bair, Attorney-in-Fact
Date:	02/12/2026

Exhibit Information

EXHIBIT 24.1 Power of Attorney for John Paul DeJoria (Incorporated by reference).